BPA Call 36E79720A0015-36C26322N0232
Award Date 11/9/21
Potential Completion Date 2/4/22
Potential Value $11K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Horsham, PA 19044, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This federal contract award is for the supply of BALVERSA (erdafitinib), a cancer treatment medication, to the Department of Veterans Affairs (VA) through the Veterans Health Administration (VHA). The prime contractor is Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., a pharmaceutical manufacturer that specializes in biologic therapies. The contract is a Blanket Purchase Agreement (BPA) established in August 2020, with a ceiling value of $3.7 million and a period of...
- This federal contract award to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., is for the delivery of BALVERSA (erdafitinib), a cancer treatment drug, to the U.S. Department of Veterans Affairs (VA). The contract has a ceiling value of $211,719.96 and a period of performance through September 30, 2025. Janssen Biotech holds two significant federal contract Indefinite Delivery Vehicles (IDVs) with the VA - a $3.7 million Blanket Purchase Agreement (BPA) and a $3.1 billion...
- The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) has awarded a firm fixed price delivery order to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., to provide the chemotherapy drug BALVERSA (erdafitinib) for patient care. The $17,642.94 delivery order was issued against Janssen's Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB). The contract has a period of performance through May 7, 2024 and was awarded on May 2,...
- This federal contract award to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., is for the delivery of the chemotherapy drug BALVERSA (erdafitinib) to the U.S. Department of Veterans Affairs (VA) and its Veterans Health Administration (VHA). The contract was awarded against Janssen's Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB), with a ceiling value of $33,080.49. This firm fixed price delivery order will support the VHA's Veterans...
- This is a firm fixed price delivery order contract awarded to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., by the Department of Veterans Affairs (VA). The contract has an ultimate completion date of November 22, 2024 and a ceiling value of $13,639.07. The contract is for the provision of the oncology drug BALVERSA (erdafitinib) to support healthcare services for veterans through the VA's Veterans Health Administration (VHA). Janssen Biotech is a major pharmaceutical...
- The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) has awarded a firm fixed price delivery order to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., for the supply of the chemotherapy drug BALVERSA (erdafitinib). This order is issued against Janssen's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract, a $3.1 billion multiple award schedule that allows VHA to procure prescription drugs. The potential value of this specific...
- The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) awarded a firm fixed price delivery order to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., for the chemotherapy drug BALVERSA (erdafitinib). This order was placed against Janssen's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract, a $3.1 billion multiple award schedule that allows VHA to procure prescription drugs to support veteran healthcare programs. The $22,053.66...
- This is a federal contract award to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., a pharmaceutical manufacturer of biologic therapies. The contract is a delivery order valued at $18,803.91 for the oncology medication BALVERSA 4 MG, awarded by the U.S. Department of Veterans Affairs (VA) through the Veterans Health Administration. The contract is a firm fixed price delivery order with no set-aside designation, issued against the Pharmaceuticals and Drugs Federal Supply...
- This federal contract award was issued by the Department of Veterans Affairs (VA) to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., a prominent pharmaceutical manufacturer. The $18,803.91 firm fixed price delivery order is for the oncology medication BALVERSA 4 MG, with a completion date of June 6, 2025. The award is part of a larger $3.1 billion multiple-award Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB) held by Janssen Biotech Inc. with...
- This federal contract award was issued by the Department of Veterans Affairs (VA) to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., a pharmaceutical manufacturer. The contract provides BALVERSA 4MG and 5MG tablets, an oncology medication, to the VA's Veterans Health Administration (VHA) through a Firm Fixed Price Delivery Order. The contract has a ceiling value of $55,400.54 and an ultimate completion date of October 31, 2023. This contract is not designated as a set-aside....